Mesenchymal stem cell application in children with subacute sclerosing panencephalitis

Area of Science:

• Neuroscience
• Immunology
• Regenerative Medicine

Background:

• Subacute sclerosing panencephalitis (SSPE) is a severe, progressive neurological disease with limited treatment options.
• Mesenchymal stem cells (MSCs) possess neurotrophic and immunomodulatory properties, suggesting potential therapeutic applications in neurological disorders.

Observation:

• This study reports the first application of MSC therapy in four patients diagnosed with SSPE.
• Patients underwent clinical follow-up, laboratory tests, electroencephalography (EEG), and magnetic resonance imaging (MRI).

Findings:

• Clinical outcomes were poor, with one patient progressing to stage III, two remaining stable, and one succumbing to the disease.
• EEG and neurological assessments correlated with clinical status, while MRI revealed new inflammatory lesions in two patients.
• The study found no demonstrable benefit from MSC treatment in this cohort of SSPE patients.

Implications:

• This preliminary investigation suggests that MSC therapy may not be effective for treating SSPE.
• Further research is needed to explore alternative therapeutic strategies for this devastating neurological condition.
• The findings highlight the critical need for rigorous clinical evaluation of novel treatments for rare and fatal diseases.